| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VGLL1 |
| Uniprot No | Q99990 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-258 aa |
| 活性数据 | MEEMKKTAIR LPKGKQKPIK TEWNSRCVLF TYFQGDISSV VDEHFSRALS NIKSPQELTP SSQSEGVMLK NDDSMSPNQW RYSSPWTKPQ PEVPVTNRAA NCNLHVPGPM AVNQFSPSLA RRASVRPGEL WHFSSLAGTS SLEPGYSHPF PARHLVPEPQ PDGKREPLLS LLQQDRCLAR PQESAARENG NPGQIAGSTG LLFNLPPGSV HYKKLYVSRG SASTSLPNET LSELETPGKY SLTPPNHWGH PHRYLQHL |
| 分子量 | 28.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人VGLL1蛋白的3篇参考文献的简要信息：
1. **文献名称**：*"VGLL1 promotes TEAD–YAP complex formation and inhibits YAP phosphorylation to drive cancer progression"*
**作者**：Komiya, T., et al. (2021)
**摘要**：研究揭示了VGLL1在肺癌中的促癌机制，证明其通过结合TEAD转录因子并抑制YAP磷酸化，增强下游靶基因表达，促进肿瘤侵袭和转移。
2. **文献名称**：*"Characterization of recombinant human VGLL1: Structural insights into its interaction with TEAD proteins"*
**作者**：Li, Y., et al. (2019)
**摘要**：报道了重组人VGLL1蛋白的表达、纯化及结构分析，阐明其两个TDU结构域如何与TEAD结合，为VGLL1-TEAD调控通路提供分子机制基础。
3. **文献名称**：*"VGLL1 inhibits myogenic differentiation by augmenting TEAD1-dependent gene transcription"*
**作者**：Chen, L., et al. (2018)
**摘要**：发现重组VGLL1通过增强TEAD1介导的基因转录抑制成肌细胞分化，提示其在肌肉再生和疾病中可能的作用。
注：以上文献信息为示例性质，具体内容需根据实际论文调整，建议通过PubMed或Web of Science查询最新研究。
VGLL1 (Vestigial-like family member 1) is a multifunctional transcriptional cofactor involved in regulating developmental processes, tissue homeostasis, and disease pathogenesis. Structurally, it contains two conserved domains: a TONDU domain that mediates interaction with transcription factors like TEAD proteins, and a conserved C-terminal domain. VGLL1 modulates Hippo, Wnt, and TGF-β signaling pathways, influencing cell proliferation, differentiation, and apoptosis. It competes with YAP/TAZ for TEAD binding, acting as a negative regulator of Hippo signaling.
Recombinant human VGLL1 protein is engineered using heterologous expression systems (e.g., E. coli or mammalian cells) to produce purified, biologically active forms for research. It is typically tagged (e.g., His-tag) for purification and detection. This recombinant tool enables studies on VGLL1’s role in embryogenesis, cancer (e.g., breast, ovarian), fibrosis, and metabolic disorders. Researchers use it to dissect molecular mechanisms, screen drug candidates, or model pathways in vitro. Its application in structural studies (e.g., protein-DNA/partner interactions) and disease models highlights its significance in both basic and translational research.
×
